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Lithium Use in Pregnancy and the Risk of Cardiac 
Malformations
To the Editor: Patorno et al. (June 8 issue)1 pro-
vided information on the risk of cardiac malfor-
mation in infants exposed to lithium during the 
first trimester of pregnancy. The risk is higher 
than in nonexposed infants or in infants exposed 
to lamotrigine, but the association is of a smaller 
magnitude than previously reported.
We emphasize that these findings do not 
imply or support the idea that lithium treatment 
should be discontinued in women who are preg-
nant or planning a pregnancy or that lithium 
treatment should be avoided in women of child-
bearing age. If properly managed, lithium is the 
most effective prophylactic treatment option for 
bipolar disorder, both in and outside the perina-
tal period, and it has a side-effect profile that is 
more favorable than usually assumed.2,3 The in-
creased risk of cardiac malformation presented 
in this research needs to be weighed against the 
high risk of a postpartum recurrence of bipolar 
disorder in women who do not receive treatment 
(in a recent meta-analysis, the risk was found to 
be 66% [95% confidence interval, 57 to 75]4), as 
well as against the risks associated with alter-
native perinatal treatment options, such as lamo-
trigine3 or the combined use of antipsychotics 
and antidepressants.5
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To the Editor: The article by Patorno et al. on 
the relationship between maternal lithium use 
and the risk of congenital cardiac malformations 
is difficult to interpret because of the incorrect 
identification of Ebstein’s anomaly, which has 
previously been linked to lithium use during 
pregnancy. Ebstein’s anomaly is distinctly not a 
form of right ventricular outflow obstruction. It 
involves the inflow portion of the right ventricle, 
not the outflow tract, and results in valvular in-
sufficiency, not obstruction. No clinician would 
classify right ventricular outflow obstruction as 
Ebstein’s anomaly because of maternal lithium 
use. Although Ebstein’s anomaly is occasionally 
associated with pulmonary stenosis or atresia, 
these are exceptions.
Thus, it is not possible to determine whether 
lithium exposure is associated with Ebstein’s 
anomaly. The authors state that none of the right 
ventricular outflow tract lesions were specifical-
ly coded as Ebstein’s anomaly. I hope not, because 
these are entirely different malformations.
The article does provide reassurance that the 
risk associated with maternal lithium use is prob-
ably lower than previously thought and seems to 
be present only when large doses of the medica-
tion are used.
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The authors reply: Di Florio et al. emphasize 
the important point that patients and clinicians 
need to balance the increased risk of cardiac 
malformations we found in our study and the 
benefits of lithium for treating bipolar disorder 
in women who are pregnant or who may poten-
tially become pregnant.1,2
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Gutgesell clarifies the anatomical characteris-
tics of Ebstein’s anomaly and gives us the oppor-
tunity to justify the classification scheme we 
used in our analyses. We examined the effect of 
lithium exposure on three different end points 
related to cardiac malformations: cardiac mal-
formations overall (primary outcome), right ven-
tricular outflow (and inflow) tract defects, and 
Ebstein’s anomaly. We combined right heart de-
fects, as had been done in other epidemiologic 
studies, because these defects might be pathoge-
netically related.3 The wide net that was cast in 
the first two levels of analysis aimed to capture 
any potential less specific effects of lithium on 
cardiac malformations. However, it is important 
to note that we also evaluated Ebstein’s anomaly 
specifically and found none in the 663 pregnan-
cies with lithium exposure. As Gutgesell con-
cludes, this finding provides reassurance, since 
the initially proposed relative risk of 400 from 
the uncontrolled International Register of Lithium 
Babies2,4 would have predicted approximately 
15 cases of Ebstein’s anomaly, given a baseline 
prevalence of 5 cases per 100,000 births.5 Our 
findings further suggest a much more modest 
association of lithium exposure, particularly at 
lower doses, with cardiac defects overall and with 
right heart defects considered as a composite 
group.
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Myeloproliferative Neoplasms
To the Editor: In his article on myeloprolifera-
tive neoplasms, Spivak (June 1 issue)1 briefly ad-
dresses the diagnostic effect of morphologic fea-
tures and states that “bone marrow histologic 
features cannot provide specificity, except that 
myelodysplasia can be ruled out on the basis of 
histologic features.” The author completely dis-
regards the World Health Organization (WHO) 
classification of myeloproliferative neoplasms, 
particularly the advancements introduced in the 
2016 revision.2 Specifically, Spivak did not men-
tion the bone marrow biopsy characteristics and 
the associated clinical effects of early-stage poly-
cythemia vera3 or the clinical relevance of prefi-
brotic myelofibrosis and its differentiation from 
essential thrombocythemia.4 Until now, none of 
the various molecular mutations have proven to be 
specific and therefore cannot be applied to the 
molecular classification of myeloproliferative neo-
plasms or used to distinguish essential throm-
bocythemia from prefibrotic myelofibrosis. The 
so-called transformation of myeloproliferative 
neoplasms, erroneously assumed by the author to 
make diagnosis a moving target — with essen-
tial thrombocythemia (i.e., early polycythemia 
vera) progressing to overt polycythemia vera or es-
sential thrombocythemia (i.e., prefibrotic myelofi-
brosis progressing to myelofibrosis) — is actually 
related to the accuracy of the initial diagnosis.5
Tiziano Barbui, M.D.
FROM Research Foundation Hospital 
Bergamo, Italy 
tbarbui@ asst-pg23 . it
Jürgen Thiele, M.D.
University of Cologne 
Cologne, Germany
Ayalew Tefferi, M.D.
Mayo Clinic 
Rochester, MN
No potential conflict of interest relevant to this letter was re-
ported.
1. Spivak JL. Myeloproliferative neoplasms. N Engl J Med 2017; 
376: 2168-81.
The New England Journal of Medicine 
Downloaded from nejm.org on September 12, 2017. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
